Adjuvant treatment for breast cancer in the elderly

Anticancer Research

Volumn 16, Issue 2, 1996, Pages 911-914

  Marchei, Paolo ^a,b   Bianco, V ^a   Pignatelli, E ^a   Chiodini, S ^a   Santini, D ^a   Carico, E ^a   Marchei, M ^a   Vecchione, A ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE   (Italy)

Author keywords

Adjuvant; Breast cancer; Chemotherapy; Elderly; Hormonotherapy; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN CITRATE;

ADJUVANT THERAPY; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; DRUG EFFICACY; FEMALE; HIGH RISK PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; TAMOXIFEN;

EID: 0029892981     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Yancik R and Ries LG: Cancer in the Aged. An Epidemiologic Perspective on Treatment Issues. Cancer 68 (Dec. 1 Suppl): 2502-2510, 1991.
2. Caruso U, Bianco V, Chiodini S, Riondino G, Veronesi S, and Giunta S: Rilievi Clinico-Epidemiologici Del Carcinoma Mammario Nelle Pazienti Anziane. Minerva Medica 86: 33-36, 1995.
3. Caruso U, Bianco V, Corsonello P, Giunta S, and Riondino G: II Cancro negli Anziani: Considerazioni Sulla Mortalità Negli Ultimi Dieci Anni in Italia. Min Med (in press).
4. Jordan VC: Estrogen receptor-mediated direct and indirect anti-tumor effects of tamoxifen. J Natl Cancer Inst 82: 1662-1663, 1990.
5. NIH Consensus conference: Treatment of early-stage breast cancer. JAMA 265: 391-395, 1991.
6. Nolvadex Adjuvant Trial Organization: Controlled trial of tamoxifen as single adjuvant agent in management of elderly breast cancer. Lancet i: 836-840, 1985.
7. Breast Cancer Trials Commitee: Adjuvant tamoxifen in the management of operable breast cancer. Lancet ii: 171-175, 1987.
8. Delosier T, Julien JP, Juret P, et al: Adjuvant tamoxifen in postmenopausal breast cancer: preliminary results of a randomized trial. Breast Cancer Res Treat 7: 105-109, 1986.
9. Early Breast Cancer Trialists' Collaborative Group: Systemic Treatment of early breast cancer by hormonal, cytotoxic, or immune therapy in 133 randomized trials involyig 31.000 recurrences and 24.000 deaths among 75.000 women. Part 1. Lancet.339: 1-15, 1992.
10. Castiglione M, Gelher RD, Goldhirsch A: Adjuvant therapy for breast cancer in the elderly: competing causes of mortality. International Breast Cancer Study Group. J Clin Oncol 8: 519-526, 1990.
11. Cummings FJ, Gray R, Danid TE, et al: Adjuvant tamoxifen vs. placebo in elderly women with node-positive breast cancer. Long term follow-up and cauces of death. J Clin Oncol 1: 29-35, 1993.
12. Fornander T, Rutquist LE, Sjaberg HE, et al: Long-term adjuvant tamoxifen in early breast cancer: Effect on bone mineral density in postmenopausal women. J Clin Oncol 8: 1019-1024, 1990.
13. Love RR, Webe DA, Newcomb PA, et al: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Inter Med 115: 860-864, 1991.
14. Me Donald CC, Stewart HJ: Fatal myocardial infarction in the Scottish adjuvant tamoxifen Trial. The Scottish Breast Cancer Committee. BMJ 303: 435-437, 1991.
15. Fisher B, Brown A, Welmark N et al: Prologing tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Project clinical trial. Am. Intern Med 106: 649-654, 1987.
16. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, citotoxic or immune therapy: 133 randomized trials involving 31.000 recurrences and 24.000 deaths among 75.000 women. Part 2. Lancet 339: 71-85, 1992.
17. Rivking SE, Green S, Metch B et al: Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10 year results of a Southwest Oncology Group Study J Clir Oncol 7: 1229-1238, 1989.
18. Boccardo F, Rubagotti A, Amoroso D et al: Chemiotherapy versus tamoxifen versus chemiotherapy plus tamoxifen in node positive, estrogen receptor positive breast cancer patients: Results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormono Therapy Cooperative Group. Eur J Cancer 28: 673-680, 1992.
19. Fisher B, Redmond C, Legault-Poisson S et al: Postoperative chemotherapy and tamoxifen compend with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Projet B-16. J Clir Oncol 8: 1005-1018, 1990.
20. Bonadonna G, Valgussa F, Moliterni A et al: Milan adjuvant and neoadjuvant studies in stage I and II breast cancer. In ́Adjuvant therapy of canceŕ. Philadelphia, Saunders, 1990.
21. Caruso U, Bianco V, Giunta S, Rizzo GL, Rizzo F: Prevenzione secondaria nei tumori della mammella: Proposta di screening. Gior Ital Oncol 3: 113-117, 1993.